^
    Back
    Association details:
    Biomarker:BRAF fusion
    Cancer:Melanoma
    Drug:sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Fusion in BRAF have also shown responses to MEK inhibitors and non specific RAF inhibitors (eg, sorafenib).